"We can turn Pax3:Foxo off in Rhabdomyosarcoma"

The Focus On Rhabdo Webinar Series continues on November 15th, 2015 at 2PM Eastern with Dr. Charles Keller. His topic of turning off the Pax3:Foxo fusion gene in aRMS should be of interest to many of us.

Cell of origin of cancers is often unknown and thus is not a consideration in treatment approaches. Alveolar rhabdomyosarcoma (aRMS) is an aggressive childhood cancer for which the cell of origin remains debated. We used genetically-engineered mouse models of aRMS to activate Pax3:Foxo1 fusion oncogene and inactivate the p53 tumor suppressor in several stages of muscle development before and after birth. These studies reveal that cell of origin significantly influences tumor appearance and susceptibility to targeted, non-chemotherapy drugs. Furthermore, this work led us to identify the histone deacetylase inhibitor entinostat as a drug for the potential conversion of Pax3:Foxo1-positive aRMS to a state akin to fusion-negative RMS by directly turning off Pax3:Foxo1.

IMPORTANT: This will be a moderated webinar. To protect our speakers from even a hint of 'practicing medicine over the internet' we ask that you send in your questions prior to the program. We will sort and compile them and try to ensure that all questions are answered - either within the talk or posed to the speaker by the moderator in the Q&A portion towards the end of the program. If you think of a question during the program, please use ClickMeeting's chat facility to ask the question and the moderator will, time permitting, ask the question to the speaker. Please use the comment form below to send your questions.

Registration is required for this program. You can register through the Events Panel on the right side of the page. You must be logged into this website to register for the program. If you didn't re-register after our crash, please take this opportunity to re-register.